Plasma Rich Growth Factors (PRGF) blood-derived eye drops have been used for some time to treat severe ocular surface disease. New research now shows PRGF to be a safe, effective, and well-tolerated treatment for mild to moderate dry eye disease according to a multi-center study published by Duke Researchers in collaboration with Baylor College of Medicine and Bascom Palmer Eye Institute.
Victor Perez, MD, study author and director of the Foster Center for Ocular Immunology discusses the findings and expanded use of hematopoietic autologous blood products in this Medpage Today® video.
“Now we're learning that we can use it [PRGF] in patients that have less symptoms, mild to moderate, to prevent progression and damage to the surface of the eye,” says Perez. “This means that not only can these drops be used to treat the symptoms of chronic dry eye, but they can also be used to prevent progression for patients with less severe symptoms.”